---
figid: PMC3079374__nihms259327f1
figlink: /pmc/articles/PMC3079374/figure/F1/
number: F1
caption: Simplified schematics of the MAPK and PI3K pathways in melanoma and the clinical
  compounds available for their inhibition. In the absence of BRAF mutations, receptor
  tyrosine kinases are activated by their ligands and activate RAS and PI3K. RAS then
  activates the RAF/MEK/ERK signaling cascade which eventually provides survival,
  proliferation, invasion, and angiogenesis advantages to melanoma tumors. BRAF mutant
  melanoma cells are sensitive to BRAF inhibitors but resistance can occur via a RAF
  isoform switch and other compensatory pathways. Combinatorial approaches targeting
  more than one molecule within one pathway or several pathways simultaneously need
  to be carefully investigated as potential treatment options for melanomas refractory
  to BRAF inhibitors. Compounds targeting the MAPK and PI3K pathways, and currently
  being tested in clinic trials, are indicated.
pmcid: PMC3079374
papertitle: 'Targeting BRAF in advanced melanoma: a first step towards manageable
  disease.'
reftext: Adina Vultur, et al. Clin Cancer Res. ;17(7):1658-1663.
pmc_ranked_result_index: '60572'
pathway_score: 0.9521741
filename: nihms259327f1.jpg
figtitle: Simplified schematics of the MAPK and PI3K pathways in melanoma and the
  clinical compounds available for their inhibition
year: ''
organisms: Homo sapiens
ndex: cc5d1c52-def1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3079374__nihms259327f1.html
  '@type': Dataset
  description: Simplified schematics of the MAPK and PI3K pathways in melanoma and
    the clinical compounds available for their inhibition. In the absence of BRAF
    mutations, receptor tyrosine kinases are activated by their ligands and activate
    RAS and PI3K. RAS then activates the RAF/MEK/ERK signaling cascade which eventually
    provides survival, proliferation, invasion, and angiogenesis advantages to melanoma
    tumors. BRAF mutant melanoma cells are sensitive to BRAF inhibitors but resistance
    can occur via a RAF isoform switch and other compensatory pathways. Combinatorial
    approaches targeting more than one molecule within one pathway or several pathways
    simultaneously need to be carefully investigated as potential treatment options
    for melanomas refractory to BRAF inhibitors. Compounds targeting the MAPK and
    PI3K pathways, and currently being tested in clinic trials, are indicated.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IRS2
  - NRAS
  - IRS4
  - RICTOR
  - KRAS
  - IRS1
  - MAPK3
  - PIK3R6
  - RPTOR
  - HRAS
  - MAP2K1
  - BRAF
  - PIK3R4
  - PIK3CG
  - PIK3R3
  - MAPK1
  - PDK4
  - AKT3
  - PIK3R5
  - ARAF
  - AKT2
  - PTEN
  - PDK1
  - PDK2
  - RAF1
  - PDK3
  - AKT1
  - MTOR
  - MAP2K2
  - PIK3CD
  - PIK3CA
  - PIK3CB
  - Temsirolimus
  - AZD6244
  - GDC-0941
  - GSK2126458
  - GDC-0980
  - Rapamycin
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS4
  entrez: '8471'
- word: Rictor
  symbol: RICTOR
  source: hgnc_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Raptor
  symbol: raptor
  source: hgnc_alias_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK4
  entrez: '5166'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: ARAF
  symbol: ARAF
  source: hgnc_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK2
  entrez: '5164'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK3
  entrez: '5165'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: AZD6244
  source: MESH
  identifier: C517975
- word: GDC-0941
  source: MESH
  identifier: C532162
- word: GSK2126458
  source: MESH
  identifier: C561454
- word: GDC-0980
  source: MESH
  identifier: C569670
- word: Rapamycin
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3079374__F1
redirect_from: /figures/PMC3079374__F1
figtype: Figure
---
